Abstract: Recent studies have showed interleukin 10 (IL-10) is a critical cytokine that determines antiviral immune response and is related to virus-associated cancers. However, whether genetically elevated circulating IL-10 levels are associated with the risk of human papilloma virus and Epstein-Barr virus-associated cancers (HEACs) is still unclear. Mendelian randomization method was implemented to meta-analyze available observational studies by employing IL-10 three variants (-592C.A, -819C.T, and -1082A.G) as instruments. A total of 24 articles encompassing 11,170 subjects were ultimately eligible for the meta-analysis. Overall, there was a significant association between IL-10 promoter variant -1082A.G and HEACs under allelic and dominant models (both P,0.01). Subgroup analysis by cancer type indicated that the risk estimate of -1082A.G was significant for nasopharyngeal cancer under allelic, homozygous genotypic and dominant models (all P,0.001). Moreover by ethnicity, carriers of -1082G allele had a 74% increased risk for nasopharyngeal cancer in Asians under dominant model (odds ratio [OR] =1.737; 95% confidence interval [CI]: 1.280-2.358; P,0.001).
Introduction
There is growing recognition that viruses are capable of causing cancer in humans, and approximately 15% of all human malignancies are estimated to be attributable to viruses, creating a major global health burden. 1 Among various cancer viruses, human papilloma virus (HPV) and Epstein-Barr virus (EBV) are exhaustively investigated and are considered to account for 38% of all virus-associated cancers. 2 HPV infection is associated with more than 90% 3 and 60% 4,5 cases of cervical and oropharyngeal cancers, respectively, and in contrast, EBV is associated with nearly 90% of nasopharyngeal cancer, 6, 7 Burkitt's, 8 and Hodgkin's lymphoma. 5, 7, 9 Moreover, the two viruses could also exhibit synergistic or cooperative effects on carcinogenesis. For example, EBV is deemed as a "helper virus" for HPV-induced carcinogenesis. 10 Coinfection of HPV and EBV was observed in 30%-50% of patients with oral cancer 11, 12 and cervical cancer.
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Qu et al Epstein-Barr virus-associated cancers (HEACs) has been universally accepted, the inherited procancer mechanisms so far remain unclear. It should be pointed out that the infection of HPV and EBV affects more than 40% of general population; however, only a small proportion of infected cases develop cancer. 15 Interindividual differences of innate antiviral immunity that is affected by hereditary factors might be involved in the underlying pathological process of HEACs. 16 Among the antiviral-relevant immune factors, interleukin-10 (IL-10) is a key cytokine that determines viral clearance or persistence 17 and is involved in carcinogenesis. 18, 19 Recent studies have observed a marked high level of circulating IL-10 in patients with HEACs and its association with poor prognosis. 20, 21 Emerging evidence suggested that interindividual differences in circulating IL-10 levels might be due to the polymorphic defects of IL-10. Recently, three variants located within IL-10 promoter region, viz, -592C.A (rs1800872), -819C.T (rs1800871), and -1082A.G (rs1800896), have been well defined in association with the changes of IL-10 production. 22, 23 It is, therefore, reasonable to hypothesize that if IL-10 is involved in the carcinogenesis process of HEACs, the inherited genetic determinants that alter IL-10 production should affect cancer susceptibility in the direction and magnitude predicted by its circulating levels.
Mendelian randomization approach, which is based on Mendel's second law, uses measured variation in genes of known function to examine the effect of a modifiable exposure on disease in observational studies. 24, 25 This method could partially provide evidence for the causal nature of the target phenotype influenced by genetic defects. To test the hypothesis that genetically elevated levels of IL-10 due to IL-10 genetic defects cause an increased risk of cancer, in this study, we first decided to perform a meta-analysis to evaluate the association of IL-10 three variants with both circulating IL-10 levels and the risk for HEACs. If the variant under study is found to be predictive of both cancer and circulating IL-10 levels, Mendelian randomization approach will be further implemented to test the possible association of circulating IL-10 levels with HEACs.
Materials and methods
This meta-analysis was undertaken according to the guidelines set forth by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Table S1 ).
search strategy
A literature search for observational studies investigating the association between IL-10 three variants (-592C.A
[rs1800872], -819C.T [rs1800871], and -1082A.G [rs1800896]) and all types of HEACs was conducted of PubMed and Google Scholar databases covering the period from the earliest possible year to August 1, 2015. Subject terms used for the search were: "interleukin 10", "interleukin-10", "IL 10", "IL-10", "oral or mouth cancer", "nasopharyngeal cancer", "oropharyngeal cancer", "Hodgkin or Burkitt lymphoma", "cervical or vaginal or vulvar cancer", "anus or anal cancer", combined with "polymorphism", "genetic", "variant", "mutation", "allele", or "genotype". The reference lists of all the retrieved articles as well as those of reviews on the same topic were also searched to supplement the additional missing articles. Searching results was limited to studies with a case-control design and articles published in the English language.
Trial selection
Two investigators (Kai Qu and Ming Zhang) independently obtained the full texts of potentially eligible articles based on the titles and abstracts. If necessary, we emailed the corresponding authors to avoid double counting of participants recruited in more than one publication. In case of more than one publication from the same study population, we abstracted data from the most recent or most complete publication.
inclusion/exclusion criteria
For inclusion, the studies should strictly fulfill the following inclusion criteria (all points must be satisfied for inclusion): 1) clinical endpoint (dependent variable): HEACs including oropharyngeal cancer, nasopharyngeal cancer, cervical cancer, Hodgkin's lymphoma, and Burkitt's lymphoma; 2) study design: either retrospective or prospective casecontrol design; and 3) independent variables: the genotype and/or allele counts of at least one of IL-10 three variants (-592C.A, -819C.T, and -1082A.G). Studies were excluded (one point was sufficient for exclusion) if they investigated the gene function, disease progression, severity, and the response to treatment or survival. Additionally, conference abstracts, case reports or series, editorials, narrative reviews, meta-analysis, and the non-English articles were also excluded.
Data extraction
Two investigators (Kai Qu and Ming Zhang) independently extracted data using a standardized Excel template. Disagreements were resolved by consensus or by a third investigator (Wenquan Niu). Data were collected on the 
G).
Weighted odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were evaluated by a randomeffects model using the DerSimonian and Laird method. Heterogeneity between studies was computed by the χ 2 test, and was quantified by the inconsistency index (I 2 ) statistic, which ranges from 0% to 100% and is defined as the percentage of the observed between-study variability that is due to heterogeneity rather than chance.
Predefined subgroup analyses were performed a priori according to the cancer types (oral cancer, nasopharyngeal cancer, cervical cancer or lymphoma [including Hodgkin and Burkitt lymphoma]), ethnicity of the study populations (Caucasian, Asian, Latinos, or African), study design (population-based or hospital-based), and the total sample size (,300 subjects or $300 subjects). The data were presented and summarized if there were three or more independent studies that provided the genotype or allele counts of the IL-10 three variants between cases and controls.
Genetic association studies have been considered more closely relevant to randomized trials than other types of epidemiological study due to independent assortment of alleles that theoretically should not be confounded by environmental or behavioral factors. 25 Therefore, we employed Mendelian randomization model to test the hypothesis that genetically elevated level of IL-10 because of variants in IL-10 cause an increased risk of HEACs. In Mendelian randomization analysis, risk estimate was computed from the ratio of the coefficient of the association between a variant and a disease to that of the association between the variant and biomarker as a reflection of the potential effect of circulating IL-10 levels on cancer risk.
Publication bias was assessed by visual inspection of Begg's and Egger's funnel plots, accompanied by the corresponding Begg's and Egger's tests. The trim and fill method was implemented to estimate the number and outcomes of potentially missing trials resulting from publication bias. Data management and statistical analyses were conducted using STATA software (StataCorp, College Station, TX, USA, version 11.2 for Windows). P,0.05 was considered statistically significant. For Begg's and Egger's statistics, a significance level was defined as P,0.10.
Results
eligible articles
A flow diagram schematizing the process of article selection with specific reasons is presented in Figure 1 . In total, 103 potentially relevant articles were identified after the initial search, and 24 of them that satisfied inclusion/exclusion criteria were deemed as eligible. All 24 qualified articles written in English were published between 2001 and 2014.
study characteristics
The basic characteristics of all 24 qualified articles are listed in Table 1 , and the genotype distributions and allele frequencies of IL-10 three variants (-592C.A, -819C.T, and -1082A.G) between cases and controls are listed in Table S2 . In this meta-analysis, 12 articles were conducted for cervical cancer, 7 for lymphoma (including Hodgkin's lymphoma and Burkitt's lymphoma), 4 for nasopharyngeal cancer, and 1 for oral cancer. Additionally, there were 8 articles involving Asians, 9 involving Caucasians, 3 involving Latinos, 2 involving Africans, and 1 involving the mixed populations. There were 11 articles conducted on a population-based design and 13 on a hospital-based design. Of 24 qualified articles, 14 (58.33%) had the total sample size (the sum of patients and controls) of at least 300 subjects.
Overall and subgroup analysis of il-10 variants and heacs
Pooling all 24 qualified articles together indicated a significant association between IL-10-1082A.G variant and HEACs submit your manuscript | www.dovepress.com
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Qu et al Table 2 ). Conversely, we failed to find any significance for the other two variants (-592C.A and -819C.T) in association with HEACs (Tables S3 and S4 ).
To account for the potential sources of between-study heterogeneity, a set of predefined subgroup analyses were conducted ( (Table 2) .
There was no publication bias of three IL-10 promoter variants either in overall or subgroup analysis as reflected by the funnel plots, Egger's tests, and Begg-Mazemdar tests (Figure 3) . association of il-10 variants with circulating il-10 levels Genotype-phenotype association was based on four articles with circulating IL-10 levels measured in HEAC cancer patients (Table S5) . 37 Figure 4 ). There were low probabilities of publication bias for both models as reflected by the Begg's funnel plots (both P=0.296) and the Egger's tests (P=0.308 and P=0.442, respectively). As expected, there were no significant differences in the changes of circulating IL-10 level for -592C.A and -819C.T under both models.
Predicted association of circulating il-10 levels with heacs from Mendelian randomization
We assumed a linear-logistic relationship between difference of circulating IL-10 level and odds of HEACs when implementing Mendelian randomization method. The predicted OR for 5 and 10 pg/mL IL-10 increment were 1.13 
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Qu et al (95% CI: 1.02-18.64) and 1.28 (95% CI: 1.05-347.26), respectively. Because the 95% CIs of both estimated OR did not include the null hypothesis value of 1.00, it was safe to reject the null hypothesis at a 5% significance level, and reveal a potential role of elevated circulating IL-10 level in development of HEACs.
Discussion
On the basis of a meta-analysis of the data from 24 studies involving 5,390 cases and 5,780 controls, we investigated IL-10 three promoter variants (-592C.A, -819C.T, and -1082A.G) and circulating IL-10 levels in relation to the risk for HEACs. One principal finding of this study was the significant association of IL-10-1082A.G variant with HEACs, especially in Asians and for nasopharyngeal cancer. On the basis of aforementioned results, we further employed -1082A.G variant as an instrument to surrogate circulating IL-10 levels, and revealed the association of IL-10 levels with risk for HEACs. To our knowledge, this is the first meta-analysis demonstrating the association between circulating IL-10 levels and HEACs by implementing Mendelian randomization approach. Previous studies have revealed that HPV and EBV infection is the main etiologic risk factors for many epithelial malignancies such as oropharyngeal cancer, 4 nasopharyngeal cancer, 6 cervical cancer, 3 and some subtypes of lymphoma such as Hodgkin's 9 and Burkitt's lymphoma. 8 HPV and EBV are ubiquitous, double-stranded DNA viruses, which can be found in the upper aerodigestive tract. Epidemiologic data showed HPV and EBV infection affected over 10% and 90% of the general population, respectively, but only a small percentage of those infected developed cancer, probably because of lowered immune response and virus clearance due to interindividual genetic variations that result in persistent virus infection. IL-10, a cytokine with multiple effects in immunoregulation and inflammation, has a central role in infection by limiting the immune response to pathogens. Given the essential role of IL-10 in the antiviral response in vitro 52 and in vivo, 17 it is reasonable to expect that IL-10 is implicated in the tumorigenesis of HEACs. Indeed, elevation of circulating IL-10 levels was detected in patients with cervical cancer, 53 OncoTargets and Therapy 2016:9 submit your manuscript | www.dovepress.com
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il-10 and hPV-/eBV-associated cancers oropharyngeal cancer, 54 and Hodgkin's lymphoma, 55 and was associated with poor prognoses of these patients. Consistent with above evidence, in this study, our pooled results using Mendelian randomization approach indicated that 5 and 10 pg/ mL increments in circulating IL-10 levels were 1.13 and 1.28 times more likely to develop HEACs in a significant manner, respectively. However, considering the unstable status of circulating IL-10 levels in time as previously described (plasma half-life ranged from 2.7 to 4.5 hours), 56 which may cause a weak association between IL-10 level and HEAC risk, well-designed studies with precise IL-10 measurement are required to quantify this effect size reliably.
Nasopharyngeal cancer is a quite common malignancy in Eastern Asians, especially in Chinese, as well as in migrants from those areas, 57 with its incidence rates peaking at 30 cases/100,000 in males and at 10 cases/100,000 in females. 58 Conversely, it is rare in Europe and North America, accounting for less than 1% of all cancer cases, with incidence rates generally below 2 cases/100,000 in males and 1 case/100,000 in females. 58 The obvious various incidence of nasopharyngeal cancer among different ethnic groups suggests this cancer is influenced by heredity factors. In this study, our results robustly confirmed the association between -1082A.G allele and nasopharyngeal cancer, especially in Asian population with relative low between-study heterogeneity. Our findings added a potential explanation for varying incidence of nasopharyngeal cancer worldwide. Further studies are necessary to confirm our findings, and IL-10-1082A.G allele, once validated, might be a specific biomarker for patients with nasopharyngeal cancer.
Despite the clear strengths including the large sample sizes and implementation of Mendelian randomization 
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Qu et al approach, several possible limitations in the present metaanalysis should also be noted. First, to avoid the impact of low-quality studies, we only included articles written in English, which might cause publication bias, even though our funnel plots and statistical tests did not tell. Second, we only examined three promoter variants in IL-10 gene, and investigation on other variants in or flanking IL-10 gene, especially some low-penetrance genes will be encouraged. Third, the single-locus-based nature of meta-analysis precluded the possibility of gene-gene 59 and gene-environment interactions, but whether this variant integrated with other genetic or environmental risk factors will enhance prediction requires additional research. For instance, it is found that different types of HPV proteins exhibited varying abilities in inducing promoter activity of IL-10 gene. 60 Therefore, it is also necessary to perform a HPV type-stratified analysis in further study. Fourth, nearly all involved studies in this meta-analysis had circulating IL-10 measured only once and did not reflect its long-term level in the development of HEACs. Therefore, because of the above limitations, the jury must refrain from drawing a firm conclusion until a large-scale and welldesigned study confirms or refutes our findings.
In summary, our findings provided evidence for a critical role of genetically elevated circulating IL-10 in the development of HEACs by employing IL-10 gene -1082A.G as an instrument, and the risk association of this variant with HEACs was more evident in Asian patients with nasopharyngeal cancer. Additional studies examining biological function of elevated circulating IL-10 level in HEACs, as well as studies seeking to provide clinical validations of our findings, are warranted. For each study, present characteristics for which data were extracted (eg, study size, PicOs, follow-up period) and provide the citations.
results: eligible articles Table 1, Tables s1 and s4 risk of bias within studies For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Table 2 synthesis of results
21
Present results of each meta-analysis done, including confidence intervals and measures of consistency. Table 2 and Tables s2, s3 risk of bias across studies 2009;6(6):e1000097. il-10 and hPV-/eBV-associated cancers Abbreviations: il-10, interleukin 10; na, not available.
